{"id":250733,"date":"2025-03-03T00:00:00","date_gmt":"2025-03-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0092-biopharma-small-cell-lung-cancer-epidemiology-emerging\/"},"modified":"2026-03-31T10:26:49","modified_gmt":"2026-03-31T10:26:49","slug":"epidon0092-biopharma-small-cell-lung-cancer-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0092-biopharma-small-cell-lung-cancer-epidemiology-emerging-markets\/","title":{"rendered":"Small Cell Lung Cancer &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of small-cell lung cancer (<abbr title=\"small-cell lung cancer\">SCLC<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the high-income countries.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> per year?<\/li>\n<li>How will improvements in survival change the number of people living with <abbr title=\"small-cell lung cancer\">SCLC<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"small-cell lung cancer\">SCLC<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 21 <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"small-cell lung cancer\">SCLC<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> by stage.<\/li>\n<li>Diagnosed incident cases of unresectable recurrent <abbr title=\"small-cell lung cancer\">SCLC<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"small-cell lung cancer\">SCLC<\/abbr>.<\/li>\n<li>Diagnosed first-line drug-treatable\u00a0<abbr title=\"small-cell lung cancer\">SCLC<\/abbr>\u00a0population.<\/li>\n<li>Diagnosed drug-treated <abbr title=\"small-cell lung cancer\">SCLC<\/abbr> population.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250733","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250733\/revisions"}],"predecessor-version":[{"id":575811,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250733\/revisions\/575811"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}